Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Syngene CFO Sibaji Biswas resigns, Deepak Jain to take over; Jayashree Aiyar appointed CSO, driving scientific strategy and ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

Global Ringworm Treatment MarketAccording to a newly-released analysis, the global ringworm treatment market is projected to ...

North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 23, 2024 /EINPresswire / -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-limited time only!

If you or a loved one took Zantac (ranitidine) and later developed health complications, particularly cancer, you may be ...

The global liquid soap market is poised for significant growth, forecasted to expand at a moderate compound annual growth ...